The price of new innovation for the treatment of multiple myeloma

Eric Low, Chief Executive of Myeloma UK, discusses recent advances in the development of new drugs for the treatment of patients with multiple myeloma and emphasises the importance of determining the cost effectiveness of new therapeutic approaches to ensure patient access.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Share this video